WHAT THIS STUDY ADDS
After evaluating the efficacy and safety of different anticoagulants in
patients with pulmonary embolism and liver dysfunction, rivaroxaban is
more suitable for this patient to be treated by sequential therapy.
This case makes a anticoagulants recommendation for patient with fatty
liver that developed pulmonary embolism.
As far as we know, this is the first reported anticoagulant therapy case
for patients with pulmonary embolism and fatty liver.
Abstract: AIMS :Patients with liver disease are more
prone to thrombosis and bleeding events than healthy people. The
decision to use anticoagulation in patients with pulmonary embolism and
liver disease requires a cautious evaluation of the risks of bleeding
and the benefits of anticoagulation. In order to make a recommendation
for patient with fatty liver that developed pulmonary embolism, we
reported this case. METHODS: In this paper, we reported a case
of a patient with fatty liver that developed pulmonary embolism. The low
molecular weight heparin sodium injection and different anticoagulants
were evaluated for this patient. RESULTS: After evaluating the
efficacy and safety of different anticoagulants in patients with
pulmonary embolism and liver dysfunction, rivaroxaban is more suitable
for this patient to be treated by sequential therapy. After three weeks
of treatment with rivaroxaban, the patient’s blood routine test results
were normal, and no side effect was found. CONCLUSIONS: For
patients with pulmonary embolism and fatty liver, maybe NOAC is more
suitable.
KEY WORDS: Pulmonary embolism; Fatty liver; Bleeding risk;
Thrombotic risk; Anticoagulant drugs; NOAC